Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1413

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Hyperglycemia

Interventions

DRUG: Metformin 500 mg bid
DRUG: Metformin 1000 mg bid
DRUG: Empagliflozin low dose qd
DRUG: Empagliflozin high dose qd
DRUG: Empagliflozin low dose bid
DRUG: Metformin 500 mg bid
DRUG: Empagliflozin high dose bid
DRUG: Empagliflozin low dose bid
DRUG: Metformin 1000 mg bid
DRUG: Metformin 500 mg bid
DRUG: Metformin 1000 mg bid
DRUG: Empagliflozin high dose bid
DRUG: Metformin 1000 mg bid
DRUG: Empagliflozin high dose bid

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]